AllianceBernstein
LXEO icon

AllianceBernstein’s Lexeo Therapeutics LXEO Stock Holding History

AllianceBernstein’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$447K Buy
77,860
+16,050
+26% +$86.8K ﹤0.01% 2793
2026
Q1 		$614K Hold
61,810
– – ﹤0.01% 2538
2025
Q4 		$614K Buy
61,810
+32,440
+110% +$296K ﹤0.01% 2557
2025
Q3 		$195K Hold
29,370
– – ﹤0.01% 3081
2025
Q2 		$118K Buy
29,370
+13,400
+84% +$44.1K ﹤0.01% 3149
2025
Q1 		$55.4K Hold
15,970
– – ﹤0.01% 3124
2024
Q4 		$105K Hold
15,970
– – ﹤0.01% 3122
2024
Q3 		$144K Buy
15,970
+5,220
+49% +$62.3K ﹤0.01% 3084
2024
Q2 		$172K Buy
+10,750
New +$156K ﹤0.01% 3056

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

AllianceBernstein's LXEO Position: Q2 2026 in Review

AllianceBernstein increased its Lexeo Therapeutics (LXEO) stake by 26% in Q2 2026, buying an estimated $86.8K and bringing the position to 77,860 shares worth $447K. The position accounts for ﹤0.01% of the portfolio, ranked #2793.

AllianceBernstein first reported a position in LXEO in Q2 2024 and has held it in 9 quarters since. The position peaked at $614K in Q1 2026. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • AllianceBernstein held 77,860 shares of Lexeo Therapeutics worth $447K as of Q2 2026.
  • AllianceBernstein bought 16,050 Lexeo Therapeutics shares in Q2 2026, an estimated $86.8K.
  • Lexeo Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2793 holding.
  • AllianceBernstein first reported a position in Lexeo Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • AllianceBernstein's Lexeo Therapeutics position peaked at $614K in Q1 2026.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.